Compounded GLP-1 drops or tablets vs injections: do the oral versions work?

Short answer: probably not reliably. FDA‑approved injectable GLP‑1s (and the one approved oral GLP‑1) have trial-proven dosing, known bioavailability and safety profiles. “Compounded” GLP‑1 drops or tablets from compounding pharmacies are unproven, often inconsistent, and carry quality/safety and legal risks.

Why injections (and one approved oral) work

• GLP‑1 receptor agonists are peptides that are poorly absorbed by the gut. Most are formulated for subcutaneous injection to get reliable blood levels. Examples with strong clinical trial evidence: semaglutide (Ozempic for diabetes, Wegovy for weight loss), tirzepatide (Mounjaro for diabetes; Zepbound for weight loss), dulaglutide (Trulicity), liraglutide (Victoza/Saxenda).
• There is one FDA‑approved oral GLP‑1: semaglutide (Rybelsus). Its formulation includes an absorption enhancer (SNAC) and has specific dosing/fasting instructions because oral peptide absorption is difficult. Rybelsus has proven, but generally smaller, effects compared with injectable semaglutide/tirzepatide.

Why compounded oral GLP‑1 drops/tablets are risky and likely unreliable

• No high‑quality clinical trials. Compounded products usually lack randomized controlled trial data demonstrating efficacy or safety.
• Potency and stability issues. Peptides degrade easily. Compounded products may have variable dose, poor shelf life, or degraded drug that won’t work.
• No guaranteed absorption enhancer. Without the approved formulation (like SNAC in Rybelsus), oral bioavailability is likely negligible.
• Contamination and sterility risk. Compounding pharmacies vary in quality. There have been FDA warnings about illicit compounding of prescription drugs.
• Legal / insurance problems. Compounded copies of FDA‑approved drugs may be legally questionable and are typically not covered by insurance.

If you’re considering an oral option

• Prefer the FDA‑approved oral: Rybelsus (semaglutide) — ask a clinician if it’s appropriate for you and follow strict dosing directions (fasting, take with a small amount of water, wait before eating or taking other meds).
• For stronger, more predictable glucose and weight‑loss effects, discuss injectable options with a clinician: Wegovy or Ozempic (semaglutide) and Mounjaro or Zepbound (tirzepatide) have more robust data for weight loss; Trulicity and Victoza are other established injectables for diabetes.
• If a compounding pharmacy offers oral GLP‑1s and you still consider it, only proceed after rigorous vetting: ask for Pharmacy Compounding Accreditation (PCAB) accreditation, USP 795/797/800 compliance, and independent certificate(s) of analysis (potency, purity, sterility) from a third‑party lab. Even then, understand the clinical evidence is lacking.

Practical next steps

1. Talk with your primary care doctor or an endocrinologist about goals (blood sugar, weight) and which evidence‑based GLP‑1 is most appropriate.
2. If you need an oral option, ask about Rybelsus first.
3. Avoid off‑label “compounded” drops/tablets unless a trusted clinician and a fully certified compounding pharmacy can verify source, testing and standards.
4. Report suspicious sellers or unexpected adverse effects to your clinician and to the FDA/your local health authority.

If you want, tell me whether your goal is diabetes control or weight loss and whether you prefer oral pills — I can outline likely effectiveness and pros/cons of specific FDA‑approved options for your situation.